티로신 키나아제 저해제의 간독성에 대한 고찰
Reviews on the Hepatotoxicity of Tyrosine Kinase Inhibitors
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Small-molecule tyrosine kinase inhibitors (TKIs) have had major impacts on anticancer therapy by targeting the catalytic activities of dysregulated tyrosine kinases. TKIs have not presented traditional toxicities; however, some serious adverse effects, including hepatotoxicity, have been documented in clinical trials and post-marketing surveillance. Although TKI-induced hepatotoxicity can cause severe clinical complications in patients, the underlying mechanism is still unclear. Methods: Studies on TKI-induced hepatotoxicity were identified by Pubmed search, and relevant articles were reviewed. Results: Immunoallergic reaction, cytochrome P (CYP) 450 polymorphisms, and formation of reactive metabolites are under consideration as mechanisms of TKI-induced hepatotoxicity. Host protein-drug metabolite conjugates are recognized as antigens by class II major histocompatibility complexes and are believed to cause liver injuries. Polymorphisms in CYP, which influences TKI metabolism, can slow TKI metabolism and may induce development of hepatotoxicity. The formation of reactive metabolites during drug metabolism can induce hepatotoxicity by directly causing cytotoxicity, leading to cell dysfunction, and indirect toxicity by mediating secondary immune reactions. Concurrent use of various medications with TKI can also cause hepatotoxicity by affecting drug transporter or enzyme activities. Conclusion: Periodic monitoring of patients taking TKIs and risk/benefit reassessments though post marketing surveillance are necessary to prevent hepatotoxicity.
Abstract
Background: Small-molecule tyrosine kinase inhibitors (TKIs) have had major impacts on anticancer therapy by targeting the catalytic activities of dysregulated tyrosine kinases. TKIs have not presented traditional toxicities; however, some serious adverse effects, including hepatotoxicity, have been documented in clinical trials and post-marketing surveillance. Although TKI-induced hepatotoxicity can cause severe clinical complications in patients, the underlying mechanism is still unclear. Methods: Studies on TKI-induced hepatotoxicity were identified by Pubmed search, and relevant articles were reviewed. Results: Immunoallergic reaction, cytochrome P (CYP) 450 polymorphisms, and formation of reactive metabolites are under consideration as mechanisms of TKI-induced hepatotoxicity. Host protein-drug metabolite conjugates are recognized as antigens by class II major histocompatibility complexes and are believed to cause liver injuries. Polymorphisms in CYP, which influences TKI metabolism, can slow TKI metabolism and may induce development of hepatotoxicity. The formation of reactive metabolites during drug metabolism can induce hepatotoxicity by directly causing cytotoxicity, leading to cell dysfunction, and indirect toxicity by mediating secondary immune reactions. Concurrent use of various medications with TKI can also cause hepatotoxicity by affecting drug transporter or enzyme activities. Conclusion: Periodic monitoring of patients taking TKIs and risk/benefit reassessments though post marketing surveillance are necessary to prevent hepatotoxicity.
참고문헌 (70)
- Krause DS, "Tyrosine kinases as targets for cancer therapy", N Engl J Med, 353(2), pp.172~187 (2005)
- Chen MH, "Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics", Circulation, 118(1), pp.84~95 (2008)
- Orphanos GS, "Cardiotoxicity induced by tyrosine kinase inhibitors", Acta Oncol, 48(7), pp.964~970 (2009)
- Cohen MH, "Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia", Clin Cancer Res, 8(5), pp.935~942 (2002)
- Shah DR, "Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy", Drug Saf, 36(6), pp.413~426 (2013)
- Shah RR, "Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval)", Drug Saf, 36(5), pp.295~316 (2013)
- Schutz FA, "Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: a metaanalysis of clinical trials", Crit Rev Oncol Hematol, 80(2), pp.291~300 (2011)
- Ghatalia P, "Hepatotoxicity with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A meta-analysis of randomized clinical trials", Crit Rev Oncol Hematol, 93(3), pp.257~276 (2015)
- Munster PN, "First study of the safety,tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors", Clin Cancer Res, 13(4), pp.1238~1245 (2007)
- Eder JP, "A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2", Clin Cancer Res, 16(13), pp.3507~3516 (2010)
- Shah RR, "Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives", Drug Saf, 36(7), pp.491~503 (2013)
- Takeda M, "Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer", Lung Cancer, 88(1), pp.74~79 (2015)
- Jackson K, "Role of cytochrome P450enzymes in the metabolic activation of tyrosine kinase inhibitors", Int J Mol Sci, 19(8), pp.2367~ (2018)
- Feng B, "Role of hepatic transporters in the disposition and hepatotoxicity of a HER2 tyrosine kinase inhibitor CP-724,714", Toxicol Sci, 108(2), pp.492~500 (2009)
- Teo YL, "Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: a meta-analysis", Cancer Treat Rev, 39(2), pp.199~206 (2013)
- Powles T, "Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: a systematic review and meta-analysis of clinical trials in advanced cancer patients", Eur J Cancer, 51(10), pp.1293~1302 (2015)
- Moy B, "Lapatinib", Nat Rev Drug Discov, 6(6), pp.431~432 (2017)
- Gunawan BK, "Mechanisms of drug-induced liver disease", Clin Liver Dis, 11(3), pp.459~475 (2007)
- Wong WM, "Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection", Hepatology, 31(1), pp.201~206 (2000)
- Levy M, "Role of viral infections in the induction of adverse drug reactions", Drug Saf, 16(1), pp.1~8 (1997)
- Spraggs CF, "HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer", J Clin Oncol, 29(6), pp.667~673 (2011)
- Schaid DJ, "Prospective validation of HLA-DRB1* 07: 01 allele carriage as a predictive risk factor for lapatinib-induced liver injury", J Clin Oncol, 32(22), pp.2296~2303 (2014)[DOI]
- Tangamornsuksan W, "HLA-DRB1*07:01 and lapatinib-induced hepatotoxicity:a systematic review and meta-analysis", Pharmacogenomics J (2019)
- Xu C-F, "HLA-B* 57: 01 confers susceptibility to pazopanib-associated liver injury in patients with cancer", Clin Cancer Res, 22(6), pp.1371~1377 (2016)[DOI]
- Xu C-F, "Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma", J Hepatol, 54(6), pp.1237~1243 (2011)
- Danielson PB, "The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans", Curr Drug Metab, 3(6), pp.561~597 (2002)
- Waxman DJ, "P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR", Arch Biochem Biophys, 369(1), pp.11~23 (1999)
- Chalasani N, "Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States", Gastroenterology, 135(6), pp.1924~1934 (2008)
- Andrade RJ, "Pharmacogenomics in drug induced liver injury", Curr Drug Metab, 10(9), pp.956~970 (2009)
- Sun F, "Drug-metabolising enzyme polymorphisms and predisposition to anti-tuberculosis drug-induced liver injury: a meta-analysis", Int J Tuberc Lung Dis, 12(9), pp.994~1002 (2008)
- Kijima T, "Safe and successful treatment with erlotinib after gefitinib-induced hepatotoxicity: difference in metabolism as a possible mechanism", J Clin Oncol, 29(19), pp.e588~e590 (2011)
- Mitsudomi T, "Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial", Lancet Oncol, 11(2), pp.121~128 (2010)
- Maemondo M, "Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR", N Engl J Med, 362(25), pp.2380~2388 (2010)
- Zhou C, "Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutationpositive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study", Lancet Oncol, 12(8), pp.735~742 (2011)
- Li J, "Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes", Clin Cancer Res, 13(12), pp.3731~3737 (2007)
- Brockmöller J, "The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment", Clin Pharmacol Ther, 72(4), pp.438~452 (2002)
- Gan SH, "Impact of CYP2D6genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics", Mol Diagn Ther, 11(3), pp.171~181 (2007)
- Swaisland HC, "Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics", Clin Pharmacokinet, 45(6), pp.633~644 (2006)
- Ju C, "Mechanism of idiosyncratic drug reactions:reactive metabolites formation, protein binding and the regulation of the immune system", Curr Drug Metab, 3(4), pp.367~377 (2002)
- Srivastava A, "Role of reactive metabolites in drug-induced hepatotoxicity", Handb Exp Pharmacol, (196), pp.165~194 (2010)
- Beaune P, "Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug", Proc Natl Acad Sci U S A, 84(2), pp.551~555 (1987)
- Kenny JR, "Drug-drug interaction potential of marketed oncology drugs: in vitro assessment of timedependent cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction prediction", Pharm Res, 29(7), pp.1960~1976 (2012)
- Dahlin DC, "N-acetyl-p-benzoquinone imine: a cytochrome P-450-mediated oxidation product of acetaminophen", Proc Natl Acad Sci U S A, 81(5), pp.1327~1331 (1984)
- Teng WC, "Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib", Mol Pharmacol, 78(4), pp.693~703 (2010)
- Li X, "Cytochrome P450-mediated bioactivation of the epidermal growth factor receptor inhibitor erlotinib to a reactive electrophile", Drug Metab Dispos, 38(7), pp.1238~1245 (2010)
- Li X, "Bioactivation of the epidermal growth factor receptor inhibitor gefitinib: implications for pulmonary and hepatic toxicities", Chem Res Toxicol, 22(10), pp.1736~1742 (2009)
- Li X, "Characterization of dasatinib and its structural analogs as CYP3A4mechanism-based inactivators and the proposed bioactivation pathways", Drug Metab Dispos, 37(6), pp.1242~1250 (2009)
- Moon JY, "Risk factors associated with the incidence and time to onset of lapatinib-induced hepatotoxicity", Breast Cancer Res Treat (2019)
- Teo YL, "Effect of CYP3A4inducer dexamethasone on hepatotoxicity of lapatinib: clinical and in vitro evidence", Breast Cancer Res Treat, 133(2), pp.703~711 (2012)
- Lee KW, "Hepatotoxicity of targeted therapy for cancer", Expert Opin Drug Metab Toxicol, 12(7), pp.789~802 (2016)
- Xu C, "Concomitant use of pazopanib and simvastatin increases the risk of transaminase elevations in patients with cancer", Ann Oncol, 23(9), pp.2470~2471 (2012)
- Dai C, "Lapatinib promotes the incidence of hepatotoxicity by increasing chemotherapeutic agent accumulation in hepatocytes", Oncotarget, 6(19), pp.17738~17752 (2015)
- Cho S, "Effects of Concomitant Medication Use on Gefitinib?Induced Hepatotoxicity", J Clin Pharmacol, 58(2), pp.263~268 (2018)
- Park BK, "The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity", Pharmacol Ther, 68(3), pp.385~424 (1995)
- Murray M, "Mechanisms and significance of inhibitory drug interactions involving cytochrome P450 enzymes", Int J Mol Med, 3(3), pp.227~265 (1999)
- Sugatani J, "Function, genetic polymorphism, and transcriptional regulation of human UDP-glucuronosyltransferase (UGT) 1A1", Drug Metab Pharmacokinet, 28(2), pp.83~92 (2013)
- Duan SX, "Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDPglucuronosyltransferase isoforms", J Pharmacol Exp Ther, 299(3), pp.998~1006 (2001)
- Mutlib AE, "Kinetics of acetaminophen glucuronidation by UDPglucuronosyltransferases 1A1, 1A6, 1A9 and 2B15. Potential implications in acetaminophen-induced hepatotoxicity", Chem Res Toxicol, 19(5), pp.701~709 (2006)
- Kostrubsky SE, "Phenobarbital and phenytoin increased acetaminophen hepatotoxicity due to inhibition of UDP-glucuronosyltransferases in cultured human hepatocytes", Toxicol Sci, 87(1), pp.146~155 (2005)
- Liu Y, "Inhibition of paracetamol glucuronidation by tyrosine kinase inhibitors", Br J Clin Pharmacol, 71(6), pp.917~920 (2011)
- Ridruejo E, "Imatinib-induced fatal acute liver failure", World J Gastroenterol, 13(48), pp.6608~6611 (2007)
- Kim DW, "Effects of imatinib mesylate on the pharmacokinetics of paracetamol (acetaminophen) in Korean patients with chronic myelogenous leukaemia", Br J Clin Pharmacol, 71(2), pp.199~206 (2011)
- Nassar I, "Reduced exposure of imatinib after coadministration with acetaminophen in mice", Indian J Pharmacol, 41(4), pp.167~172 (2009)
- Méndez-Vidal MJ, "Management of adverse events of targeted therapies in normal and special patients with metastatic renal cell carcinoma", Cancer Metastasis Rev, 31(1), pp.19~27 (2012)
- Klempner SJ, "Severe pazopanib-induced hepatotoxicity: clinical and histologic course in two patients", J Clin Oncol, 30(27), pp.e264~e268 (2012)
- Pariente A, "Imatinib mesylate-induced acute hepatitis in a patient treated for gastrointestinal stromal tumour", Eur J Gastroenterol Hepatol, 18(7), pp.785~787 (2006)
- Seki N, "Promising new treatment schedule for gefitinib responders after severe hepatotoxicity with daily administration", J Clin Oncol, 24(19), pp.3213~3214 (2006)
- Chen X, "Rechallenge with gefitinib following severe drug-induced hepatotoxicity in a patient with advanced non-small cell lung cancer: A case report and literature review", Oncol Lett, 7(3), pp.878~880 (2014)
- Ku GY, "Successful treatment of two lung cancer patients with erlotinib following gefitinib-induced hepatotoxicity", Lung Cancer, 70(2), pp.223~225 (2010)
- Gupta-Abramson V, "Phase II trial of sorafenib in advanced thyroid cancer", J Clin Oncol, 26(29), pp.4714~4719 (2008)